Incyte Acquire Genome Systems

28 July 1996

- Incyte Pharmaceuticals has acquired Genome Systems, a USA-based genomics company. The acquisition enables Incyte to accelerate its gene sequence mapping program using Genome Systems' human DNA libraries and mapping capabilities. With 1995 sales of $2 million, Genome Systems will retain its name and become a wholly-owned subsidiary of Incyte, which is to issue 200,000 shares of common stock in the acquisition. Meanwhile, Incyte has announced a three-year mapping collaboration with Vysis.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight